Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

John W. MacArthur, Amanda N. Steele, Andrew B. Goldstone, Jeffrey E. Cohen, William Hiesinger, Y. Joseph Woo

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Over the past two decades, the field of cardiovascular medicine has seen the rapid development of multiple different modalities for the treatment of ischemic myocardial disease. Most research efforts have focused on strategies aimed at coronary revascularization, with significant technological advances made in percutaneous coronary interventions as well as coronary artery bypass graft surgery. However, recent research efforts have shifted towards ways to address the downstream effects of myocardial infarction on both cellular and molecular levels. To this end, the broad application of injectable hydrogel therapy after myocardial infarction has stimulated tremendous interest. In this article, we will review what hydrogels are, how they can be bioengineered in unique ways to optimize therapeutic potential, and how they can be used as part of a treatment strategy after myocardial infarction.

Original languageEnglish
Article number30
JournalCurrent Treatment Options in Cardiovascular Medicine
Issue number4
StatePublished - 1 Apr 2017
Externally publishedYes


  • Coronary artery bypass
  • Graft surgery
  • Hydrogel therapy
  • Ischemic cardiomyopathy


Dive into the research topics of 'Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy'. Together they form a unique fingerprint.

Cite this